PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Infectious Disease and Vaccines, Merck and Company, Inc., Kenilworth, NJ 07033.\', \'Infectious Disease and Vaccines, Merck and Company, Inc., Kenilworth, NJ 07033 dai_wang@merck.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • e202586611810.1073/pnas.2025866118
?:doi
?:hasPublicationType
?:journal
  • Proceedings of the National Academy of Sciences of the United States of America
is ?:pmid of
?:pmid
?:pmid
  • 33766889
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.092
?:rankingScore_hIndex
  • 675
is ?:relation_isRelatedTo_publication of
?:title
  • Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33766889>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33766889>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all